Olema Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Olema Pharmaceuticals, Inc. filed a Form 8-K on March 9, 2023, under Item 2.02 to report financial results for the year ended December 31, 2022. The company is listed on The Nasdaq Global Select Market under the symbol OLMA.
Financial results and liquidity
The filing references a March 9, 2023 press release containing the company’s 2022 financial results, furnished as Exhibit 99.1. The provided filing text does not include clear values for revenue, net income or loss, operating expenses, cash flow, cash and equivalents, debt, liquidity, margins, or other financial metrics.
Material changes versus the prior comparable period
The filing text does not provide quantitative or qualitative details regarding changes from the prior year.
Guidance, outlook, risks, and unusual items
The provided text contains no guidance, outlook, management commentary, risk updates, contingencies, or unusual items. Any such information may be included in the referenced Exhibit 99.1 press release, which is not reproduced in the source text.
Important facts for investors to verify
- Review Exhibit 99.1 for the complete fiscal-year 2022 financial results and management commentary.
- Verify reported cash, cash runway, operating cash use, and any financing activities.
- Check for revenue, research and development expenses, general and administrative expenses, net loss, and loss per share.
- Review any 2023 clinical, regulatory, development, or corporate outlook included in the press release.
- Note that the Item 2.02 information and attached press release were furnished, not filed, for purposes of Section 18 of the Exchange Act and were not incorporated by reference into other SEC filings.